Background: Onychomycosis is a relatively common condition affecting toenails more than fingernails. It is caused predominantly by dermatophytes. Onychomycosis can cause pain and discomfort and has the potential to be a source of morbidity.
J AM ACAD DERMATOL VOLUME 43, NUMBER 4 immunocompetent individuals. Onychomycosis may have medical significance especially in some disease states such as diabetes and others where the individual is immunocompromised. 14 Also, onychomycosis can have a substantial effect on the activities of daily living, such as ambulation. 15 In the United States, griseofulvin and ketoconazole were the only available treatments approved for onychomycosis until oral itraconazole became available for this indication in October 1995. 16, 17 Subsequently, oral terbinafine was approved for the treatment of tinea unguium in May 1996. Oral fluconazole is not approved in the United States for this indication. Ciclopirox nail lacquer is the first non-oral agent approved in the United States for the management of onychomycosis. This article focuses on the 2 pivotal studies conducted in the United States that confirmed the efficacy and safety of ciclopirox nail lacquer for the treatment of mild to moderate toenail onychomycosis. In addition, results from non-US studies are also summarized.
Two identically designed, double-blind, vehiclecontrolled, parallel group, multicenter studies were performed to evaluate the use of ciclopirox nail lacquer in individuals with a diagnosis of mild to moderate distal subungual tinea unguium of at least one great toenail. These two pivotal trials were conducted in the United States to meet the regulatory requirements necessary for confirming the efficacy and safety of an investigational drug.
MATERIALS AND METHODS FOR THE UNITED STATES STUDIES

Study design
Baseline evaluation included recording information such as demographic data, medical history, duration of onychomycosis, and the presence or absence of chronic tinea pedis. A physical examination was conducted; clinical laboratory and mycologic sampling was carried out, ensuring that the eligibility criteria were met. Each eligible subject was randomly assigned to receive either the active treatment or matching vehicle for 48 weeks. Subjects reported to the clinic for evaluations by the physician every 4 weeks. If a subject had a clinically and mycologically cured target nail (treatment cure) at the conclusion of the 48 week treatment period, the C iclopirox and its salt ciclopirox olamine are hydroxypyridone derivatives that differ chemically and mechanistically from other marketed antifungal agents such as the azoles and the allylamines. [1] [2] [3] [4] [5] Unlike most antifungals currently available, ciclopirox does not affect sterol biosynthesis. Ciclopirox is glucuronidated and is not metabolized via the cytochrome P 450 pathway. The novel antifungal action of ciclopirox involves chelation of polyvalent cations (such as Fe 3+ ) with inhibition of metal-dependent enzymes responsible for the degradation of toxic peroxides in the fungal cell. 6 Ciclopirox is a broad spectrum antifungal agent that is effective against the major human fungal pathogens responsible for onychomycosis. [7] [8] [9] [10] [11] In fact, ciclopirox is fungicidal in vitro to strains of Trichophyton rubrum, T mentagrophytes, and Epidermophyton floccosum, the fungal species typically implicated as the causative organisms in onychomycosis. 7 In vitro, ciclopirox is also effective against Candida sp and nondermatophyte molds, for example, Scopulariopsis brevicaulis, Aspergillus sp, and Scytalidium hyalinum. 9, 10 Ciclopirox olamine was first introduced to the market in April 1975, and is now marketed in more than 70 countries worldwide. Ciclopirox olamine has been marketed as a 1% cream and lotion in the United States for 15 years and worldwide for 24 years. It was recently approved as the 0.77% gel in the United States. Ciclopirox nail lacquer topical solution 8% (also referred to in this article as ciclopirox nail lacquer) was first approved for use in France in 1991. Since then, the product has been approved for use in over 40 countries and has most recently been approved in the United States in December 1999 for the topical treatment of mild to moderate onychomycosis of fingernails and toenails without lunula involvement in immunocompetent individuals infected by T rubrum.
Onychomycosis is a common condition; some estimates suggest that it affects approximately 6% to 13% of the North American population. 12, 13 Onychomycosis is present predominantly in toenails rather than fingernails, in males, and in the elderly, and is most commonly caused by T rubrum. Invasive nail disease caused by molds is less common in North American series. Candida sp are more likely to cause invasive nail disease in fingernails than toenails in visit the target nail was trimmed to at least the distal groove or an onycholytic nail was trimmed to the point of attachment. Any excess horny material was filed from the nail surface before treatment application. Excessive debridement or drilling of nails was not permitted. As per protocol, fungal infections besides onychomycosis (eg, tinea pedis or tinea cruris) were treated with ciclopirox olamine cream 1%. Subjects were not allowed to apply any product other than the nail lacquer on the treated nails.
Method of assessment
The efficacy variables pertained to the target nail and included the KOH examination and fungal culture of material obtained from the nail, planimetric measurement of the involved area, and a physician's global evaluation. The global evaluations were performed at each 4 week clinic visit, whereas the mycologic evaluations and photographic planimetry measurements were performed every 12 weeks during the 48 week treatment.
Planimetry
Computerized planimetric measurements of the involved area of the target nail were made from standardized photographs and analyzed at a central laboratory in a blinded fashion. Using a fine point felt tip pen, the investigator outlined the portion of target nail that was clinically involved and the boundary of the hyponychium or nail groove. The photographs were scanned into a computer and a planimetric measurement of the area of target nail involved was performed. The affected area (which included visually involved nail plus any area of missing nail because of trimming back from the distal groove) as a percentage of the whole nail area was used for the analysis. Computerized photoplanimetry is reproducible; however, because areas are delineated by ink lines with a finite thickness, and because the final length of the healthy nail can only be presumptive, loss of precision is inevitable as a treatment cure is approached. Thus, planimetry cannot be used to distinguish minimal residual disease from cure. Hence, the establishment of cure remained a clinical decision.
Global evaluation score
The global evaluation score (GES) of the target nail was assessed visually by comparing subsequent evaluations to the Day 1 (baseline) evaluation. The 5-point grading scale was, 0 = cleared (100% clearance of clinical signs of disease corroborated by an absence of investigator markings on the photograph), 1 = excellent improvement (≥ 75% but <100% clearance of clinical signs of disease), 2 = patient was eligible for post-treatment follow-up evaluations for a 12 to 24 week period.
Inclusion criteria included individuals age 18 to 70 years with distal subungual tinea unguium of at least one great toenail (target nail). Before randomization, patients were to have clinical evidence of onychomycosis with positive potassium hydroxide (KOH) preparation and positive dermatophyte culture. Subjects had between 20% to 65% area of target nail involved (confirmed by computerized planimetry of standardized photographs). Subjects were excluded if either white superficial or proximal subungual onychomycosis was present. Also excluded were subjects with abnormalities of the target nail that could have prevented obtaining a normal appearing nail if complete cure of the tinea unguium was achieved. Similarly, individuals with a structural deformity of the target nail or foot that could interfere with photography or planimetric analysis were excluded. An individual with a "spike" of onychomycosis extending to the cuticle of the target nail could not enter the study. A patient with a history of immunosuppression or clinical signs indicative of possible immunosuppression was not allowed to enroll in the study.
Subjects were not allowed to use systemic antifungal therapy within 24 weeks before the screening visit; however, local treatment of vaginal candidiasis and the use of ciclopirox olamine cream 1% for treating flares of tinea pedis were allowed. Patients could not use topical antifungal therapy within 14 days of the screening visit; however, no washout period was required for ciclopirox olamine cream 1%.
Treatment procedures
The test material was applied daily, approximately 24 hours apart, with the lacquer brushed on all toenails and any affected fingernails. Subjects were instructed to apply the material to all toenails regardless of involvement. The areas covered with the lacquer were the entire nail plate and approximately 5 mm of adjacent skin. If possible, the material was applied to the nail bed, the hyponychium, and the ventral surface of the nail plate where it was free of the nail bed. Patients were to wait at least 8 hours after application of the lacquer before washing the feet.
The nail lacquer was not removed on a daily basis; rather daily applications were applied over the previous coat. Every 7 days subjects were instructed to completely remove the lacquer with isopropyl alcohol swabs, file away any loose nail material, and trim the nails as necessary.
Normal hygiene and foot care practices were permitted. No occlusive dressings were allowed. At each S72 Gupta, Fleckman, and Baran moderate improvement (≥ 50% to <75% clearance of clinical signs of disease), 3 = slight improvement (<50% clearance of clinical signs of disease), 4 = no change (no detectable improvement from baseline evaluation), and 5 = exacerbation (flare of area being studied or increase in area of involvement).
Efficacy criteria
The efficacy criteria pertained to the target toenail and were based on the following: fungal culture, light microscopic examination (KOH exam), physician's GES, and affected area as a percentage of the whole nail plate area (planimetry). The primary efficacy variable was treatment success (defined as simultaneous negative KOH and culture, and ≤ 10% area involvement of the target nail plate as determined by planimetry). Other secondary variables included: treatment cure (defined as simultaneous negative KOH and culture, and a GES of cleared), mycologic cure (defined as simultaneous negative KOH and culture), and negative mycologic culture.
Safety criteria
Adverse events (AEs) were recorded during the study, and were defined as any signs, symptoms, illnesses, or diagnoses that appeared or worsened. For example, flares of tinea pedis, skin irritation adjacent to the treated nails, or nail bed irritation were reported as AEs. All AEs that occurred at any time during the study, whether believed by the investigator to be related or unrelated to the test material, were reported as an AE. For the safety analysis, only treatmentemergent AEs (TEAEs) were considered. This included any AE occurring during treatment that was not present before treatment or was present before treatment but became more intense (that is, increased in severity or frequency) during the treatment period. In addition to continuous AE monitoring, clinical laboratory evaluations (complete blood count, serum chemistry including liver function tests and electrolytes, and urinalysis) were performed every 12 weeks during the 48 week study. At selected study sites blood samples were collected before, during, and after treatment for measurement of serum levels of ciclopirox and its glucuronide metabolite.
Statistical analysis
Descriptive statistics were used to summarize the patients' demographic characteristics (age, gender, race) and the background characteristics (percent area of involvement of the target great toenail, duration of onychomycosis, causative organism, presence/absence of tinea pedis). Area of involvement at baseline (less than or greater than 40% of nail surface) was also used as a stratification variable in the efficacy analyses. The age of the subject, percentage involvement of nail plate at the baseline visit, and the duration of onychomycosis were considered as continuous variables and compared by means of the analysis of variance (ANOVA) between the 2 treatments without any adjustments. The other variables Gupta, Fleckman, and Baran S73 J AM ACAD DERMATOL VOLUME 43, NUMBER 4 
analysis (ciclopirox: 119 subjects, vehicle: 118). Of the patients randomized to treatment in this study, 96 (80.7%) and 94 (79.7%) completed the study, respectively. None of the 231 patients receiving the ciclopirox treatment in either study discontinued the study prematurely because of an AE. The primary reasons for being withdrawn from the study for both the ciclopirox and vehicle groups included: withdrawal of consent, unreliability, violation of protocol criteria, lost to follow-up, and lack of efficacy. Demographic and baseline characteristics for study I and study II are presented in Table I . Population characteristics were homogenous between the two treatment groups (P > .05) and consistent across studies. The studied population was predominantly male (approximately 80%), with a mean age of approximately 49 years. In addition, the mean area of involvement for the target toenail was approximately 40%, and the predominant causative pathogen was T rubrum.
The most frequently used non-study medication was ciclopirox olamine cream 1%, for the treatment of any tinea pedis flares that may have occurred durwere considered as categorical and the CochranMantel-Haenszel test adjusted for the investigator site was used. All subjects who had received at least one dose of the randomized study medication were included in the intent-to-treat (ITT) population. The primary time point of interest was end of treatment (typically week 48), although interim time points were also analyzed. This conservative approach (known as a Last Observation Carried Forward method of analysis) assumed that a subject would not have achieved treatment success or treatment cure if he or she remained in the study.
RESULTS OF US STUDIES
Study patients
In the first study (Study 312), a total of 223 individuals were randomized to treatment and were included in the ITT analysis (ciclopirox group: 112, vehicle group: 111). Of the patients randomized to treatment, 89 (79.5%) and 84 (75.7%) completed the study for the active and vehicle group, respectively. Similarly, 237 subjects were randomized to treatment in study II (Study 313) and were included in the ITT ing the 48 week study. Approximately 61% to 75% of the patients used this concomitant treatment at one time or another during the conduct of the studies. The use of this therapy was relatively high because it was a therapy provided per protocol to treat the tinea pedis infections that commonly accompany onychomycosis.
Efficacy
The incidence of mycologic cure, treatment success, treatment cure, and negative mycology cultures at the end of treatment through 48 weeks is presented in Table II . These data indicate that ciclopirox nail lacquer is an effective treatment of mild to moderate onychomycosis of the toenail. Although the data presented focus on the week 48 endpoint, significant improvements were realized as early as week 12 for the mycologic cure and negative mycologic culture responses (P < .001; ciclopirox nail lacquer vs vehicle). These significant improvements were maintained throughout the entire 48 week treatment period. Outcomes for patients with greater (40% to 65% nail surface area involved) and lesser (20% to <40% nail area) severity of disease were also analyzed and showed results similar to the population as a whole. Of the 17 patients who were eligible for follow-up after treatment (ie, those meeting the stringent "treatment cure" criteria), many had incomplete data to adequately assess the relapse rate. However, 7 of the 12 patients with complete data remained "cured" at 12 weeks after treatment. Alternately, 4 of 12 patients did not maintain negative mycology (ie, negative KOH and culture) at 12 weeks after treatment. One patient had negative mycology and was recorded to have "almost clear" toenails.
Safety
The TEAEs reported by more than one patient and considered by the investigator to be possibly related to the test material are presented in Table III . Typically the "rashes" reported as TEAEs consisted of erythema in the skin adjacent to the nail plate. Most of the reported erythema cases (coded as rash) were mild in severity and generally cleared by the end of the study. Application site reactions were occasionally recorded for both the ciclopirox and vehicle, and were mild in intensity. These local reactions generally consisted of a tingling sensation, pain, or intermittent burning, and were transient and cleared during therapy without requiring specific treatment. Nail disorders were infrequently reported for both the ciclopirox and vehicle groups, and typically consisted of changes in nail shape or color without requiring any specific treatment. These were mild in intensity and cleared during the course of the study without necessitating treatment or discontinuation from the protocol.
In both studies, there were no serious AEs considered causally related to the ciclopirox nail lacquer, and none of the subjects in the ciclopirox group in either study discontinued therapy because of TEAEs. There were no suggestive trends or important differences between treatments for any clinical laboratory evaluation.
Ciclopirox nail lacquer is considered extremely safe as demonstrated by the pivotal US studies. AEs that have been observed are generally localized and consist primarily of erythema, and even less frequently, burning/tingling sensation or swelling at the application site. In most instances these are mild in intensity and clear with continued application of the lacquer.
NON-US TRIALS CONDUCTED TO DETERMINE THE EFFICACY AND SAFETY OF CICLOPIROX NAIL LACQUER
Thirteen trials that have been conducted outside of the United States using ciclopirox nail lacquer to treat onychomycosis of fingers and toes are summarized in Table IV . The majority of patients had toe onychomycosis caused by dermatophytes. The countries in which these trials were conducted included Europe (Germany, France, Finland, and Austria), Asia (Korea), North America (Mexico), and South America (Argentina and Brazil). The 13 non-US studies used a variety of trial designs. Although most were open label, they were frequently multicenter studies with standardized techniques for efficacy evaluations. In addition, safety was assessed by adverse experiences captured in the studies. Qualified study patients generally were to have clinical, microscopic, and culture evidence of onychomycosis. This usually meant that patients were to have culture evidence for dermatophytes, although some patients having nondermatophyte organisms (eg, Candida sp) or negative fungal cultures were included. Although a specified surface area involvement was not a requirement, the majority of patients had evidence of extensive nail involvement (>2/3 of nail surface) at baseline. Treatment regimens in the non-US studies varied, with some studies using a less frequent regimen than the once daily 48-week treatment studied in the US. In addition, the typical treatment duration was usually 6 months for the non-US studies. Outcome measures (physician and patient assessments, and mycology) were similar to those used in the US trials, although a nonphotographic planimetric method was used to quantify disease extent.
Results of the non-US studies demonstrated the efficacy of ciclopirox nail lacquer across a range of ment of onychomycosis in the great toe, which is usually difficult to treat because of disease extent, high rates of reinfection, and slow nail growth rates. In addition, the efficacy of ciclopirox nail lacquer has been confirmed in several non-US studies. In the US studies, the nail lacquer was applied daily for 48 weeks; whereas in non-US studies, less frequent applications for shorter durations have been used successfully.
In the US studies, the evaluation of the target nail involvement was performed from computerized planimetric measurements obtained from standardized photographs. The investigator outlined the portion of target nail that was clinically involved and the boundary of the hyponychium or nail groove using a fine point felt tip pen. In these protocols, the area of involvement may have been overestimated as the patient approached a cleared nail because the affected area included not only the abnormal-appearing nail plate but also any area of missing nail that had been trimmed back during manicuring. In studies evaluating the efficacy of other drug comparators, the method of assessing the area of nail plate involved included: estimation to the nearest 10%, 18 rating the percentage of nail involvement on a scale of 0 to 5 (0 = 0%, 1 = 1% to 24%, 2 = 25% to 49%, 3 = 50% to 74%, 4 = 75% to 99%, and 5 = 100%), 19 and a clinical evaluation of the percent of nail involved. 20 The differences in the methodology used treatment regimens (Fig 1) . Although many studies used a once daily treatment course, as used in the United States, efficacy was also seen when the product was applied on a twice or thrice weekly basis. The study populations were more heterogeneous than those of the 2 pivotal US trials, with a broader variety of causative organisms. Response to treatment with the nail lacquer was evident in that mycologic cures, as well as clinical responses ('clinical cure' or marked improvement) were seen after approximately 6 months of treatment. In patients followed after treatment completion, good clinical effects were maintained in about half the patients for the post-treatment observation period of 1 to 7 months. In fact, a meta-analysis of the relapse rates including the US studies indicates an average relapse rate of 20.7% at up to 6 months after discontinuation of therapy. As in the US experience, the nail lacquer was very well tolerated at all centers, demonstrating no systemic toxicities and with minimal local side effects.
DISCUSSION
Data from the pivotal US trials have demonstrated that ciclopirox nail lacquer is significantly more effective than placebo (vehicle) in the treatment of mild to moderate toe onychomycosis without lunula involvement, caused by T rubrum. These studies establish the efficacy of the nail lacquer for the treat- to evaluate efficacy suggest that caution should be exercised when trying to compare results from separate studies without carefully looking at the manner in which the results have been derived. In the non-US studies, the area of target nail plate that was diseased was assessed visually with the aid of manual calibration. This may explain in part differences seen in efficacy rates between the US and non-US studies. Furthermore, in the non-US studies the area of nail plate involved at baseline was in many cases higher than in the US studies. It can be speculated that individuals in non-US studies, many of whom had more extensive nail involvement, demonstrated a higher response because of better penetration of ciclopirox nail lacquer through abnormal or dystrophic nail as compared with nail that has normal architecture. Studies using fluconazole, terbinafine, and itraconazole have demonstrated that there is a correlation between treatment outcome and concentration of drug in the nail plate. [21] [22] [23] Therefore, it is possible that a more severely affected nail may in fact have a higher concentration of drug in the nail plate resulting in a better than expected response. In the US studies, disease was limited to less than 65% nail area involvement; within that range efficacy was similar between greater and lesser amounts of disease.
Ciclopirox nail lacquer is a broad spectrum agent with efficacy against yeasts and other nondermatophyte molds, in addition to dermatophytes. [7] [8] [9] [10] [11] This broad spectrum coverage is an important consideration, especially when the etiologic agent for the onychomycosis is not clear or has not been determined. The effectiveness of ciclopirox nail lacquer against Candida sp may be particularly important in the treatment of fingernail onychomycosis. 11 Ciclopirox nail lacquer is considered extremely safe as demonstrated by the pivotal US studies and studies worldwide. AEs that have been observed are generally localized and consist primarily of erythema, and even less frequently, burning/tingling sensation, or swelling at the application site. In most instances these are mild in intensity and clear with continued application of the lacquer. Although the oral antifungal agents are generally safe, systemic adverse effects have been reported. Occasionally, these have been of a serious nature (eg, symptomatic hepatitis, blood dyscrasia, or a severe cutaneous eruption such as erythema multiforme or toxic epidermal necrolysis). [1] [2] [3] 16, 17 Ciclopirox nail lacquer has not been associated with any drug-drug interactions, whereas oral antifungal medicines have been associated with significant interactions. The systemic absorption of ciclopirox is extremely low with rapid metabolism of J AM ACAD DERMATOL VOLUME 43, NUMBER 4 any drug that is absorbed. Glucuronidation is the main metabolic pathway; therefore, interactions with drugs that are metabolized via the cytochrome P 450 system are unlikely. 24, 25 Ciclopirox nail lacquer is easy to apply and should be brushed on the dorsal aspect of the nail plate of all nails that appear to have onychomycosis. In the US studies, the lacquer was applied to the nail folds and the ventral and dorsal aspects of the infected nail plate. Experience outside the United States suggests that the lacquer is effective when the application is confined to the dorsal and distal ventral nail plate. Application to the nail folds is more likely to produce localized AEs. The nails should be trimmed with regular removal of the unattached, infected nail by a health care professional, or by the patient, thus helping to maximize the beneficial effects. This application strategy, in fact, mimics the routes of entry of the targeted dermatophytes. Because the product is easy to apply, post-marketing experience in countries where the drug is approved has, in general, demonstrated high compliance.
Ciclopirox nail lacquer may be useful in the treatment of patients who are not good candidates for an oral antifungal agent (eg, those with hepatic or renal disease or blood dyscrasias; those receiving multiple oral agents; and those in whom oral antifungal therapy has failed). Furthermore, ciclopirox nail lacquer may be of benefit for patients who exhibit a relapse/reinfection of the onychomycosis after other treatments. It is also possible that the ciclopirox nail lacquer may be a useful combination therapy with oral antifungal agents, although further studies are necessary to explore the potential for synergism of these two combined routes of administration.
In conclusion, studies conducted worldwide demonstrate the efficacy of ciclopirox nail lacquer for the treatment of finger and toe onychomycosis. Both controlled and open-label studies confirm the excellent safety profile of this topical therapy. Thus, the nail lacquer provides a treatment choice with a favorable benefit-to-risk ratio. With its novel mechanism of action and its topical route of administration, ciclopirox nail lacquer offers an innovative approach to the treatment of this often difficult-to-manage disease.
